{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MGNX",
  "name": "MacroGenics, Inc.",
  "url": "https://frontierpicks.com/dossiers/MGNX/",
  "json_url": "https://frontierpicks.com/dossiers/MGNX.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "MGC026's head-and-neck cohort cleared its pre-specified Stage 1 threshold on 2026-07-23 and the interim Phase 1 data lands as ESMO poster 1020P on 2026-10-23; the name walks in with $327M pro forma cash (2026-06-30) built from the Bora sale, a Gilead option payment and a Sanofi milestone rather than equity issuance, and runway guided through 2028.",
  "invalidation_trigger": "A weekly close below $3.90 (unwinds the three-month advance and returns price to the pre-2026-07-23 range); secondarily, ESMO poster 1020P on 2026-10-23 passing with SCCHN data that does not extend beyond the Stage 1 bar, or an equity raise priced into strength.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Revenue is milestone- and royalty-shaped (Gilead, Sanofi/TZIELD), so quarterly sales swing widely against consensus — Q2 2026 printed $32.8M vs a $67.5M estimate.",
    "63,645,711 shares outstanding per the Q2 2026 report; cash runway guided through 2028 after the Bora manufacturing sale.",
    "Manufacturing is fully outsourced following the Bora Biologics transaction; headcount is approximately 140 post-restructuring.",
    "Board member Karen Ferrante, M.D. resigned effective 2026-09-01, stated as personal reasons with no disagreement over operations or policies (8-K).",
    "Development of vobramitamab duocarmazine was discontinued in Q1 2026; MGC026 is the company's second B7-H3-directed ADC to reach cohort expansion."
  ],
  "body_markdown": "## Current Thesis\n\nThe narrative leg on offer is a restructured, cash-covered ADC developer walking into one dated data slot. On 2026-07-23 MacroGenics disclosed that the squamous-cell head-and-neck (SCCHN) cohort of its Phase 1 MGC026 study cleared the pre-specified Stage 1 response threshold of a Simon two-stage design with a 40-patient target, at 7.5 mg/kg every three weeks. That interim dataset is scheduled as poster 1020P at ESMO Congress 2026 in Madrid on 2026-10-23, 15:15–16:00 CEST, lead author Rachel E. Sanborn. Behind it sits a balance sheet rebuilt without equity: the 2026-08-13 Q2 release reported $173.3M of cash and marketable securities at 2026-06-30 and $327M pro forma including the Bora, Sanofi and Gilead proceeds, with runway guided through 2028.\n\nThe narrative is accelerating — three fresh dated items landed inside five weeks (the 07-23 Stage 1 threshold, the 08-11 Gilead option exercise, the 08-17 B. Riley target raise to $11), the shares closed 2026-09-04 at $4.40 with RSI(14) at 62.1 and only 9.5% below the 52-week high of $4.86, and the event that the attention is pointed at has not happened yet.\n\n## Bull Case\n\n- **2026-07-23:** MGC026 SCCHN cohort met the pre-specified Stage 1 threshold and moved into Stage 2 enrolment (Simon two-stage, 40-patient target, 7.5 mg/kg q3w). As of 2026-07-08, 74 patients had been enrolled across dose escalation and cohort expansion, with no interstitial lung disease and no ocular toxicity reported — the two toxicities that have historically constrained this ADC class.\n- **2026-08-13 (Q2 release):** pro forma cash, cash equivalents and marketable securities of $327M against $173.3M on the balance sheet at 2026-06-30, with runway stated through 2028. The build came from asset sale and partner payments, not a follow-on: $119.6M received at closing on the Bora Biologics manufacturing sale ($122.5M base price), a $10.0M Gilead option payment, and a $24.5M Sanofi regulatory milestone on TZIELD.\n- **Cost structure cut, not trimmed:** headcount of approximately 140 after the restructuring, manufacturing fully outsourced. Q2 SG&A was $7.9M against R&D of $38.8M — the spend that remains is concentrated in the clinic.\n- **2026-08-11:** Gilead Sciences exercised its option for an exclusive licence to a preclinical bispecific under the 2022 collaboration, triggering the $10M payment — a partner paying to advance platform output while the wholly-owned assets read out.\n- **2026-08-17:** B. Riley Securities maintained Buy and raised its price target to $11.\n- Three further tumour cohorts (endometrial, melanoma, soft-tissue sarcoma) are running at the same dose, so the 10-23 poster carries more than one shot on goal.\n\n## Bear Case\n\n- **The Q2 top line missed badly.** Revenue of $32.832M against a $67.456M estimate, and adjusted EPS of $(0.27) against $(0.13) (Benzinga, 2026-08-13). The 2026-08-13 release also carried a reported net income line of $19.5M; the two figures are not comparable without the one-time items from the Bora closing, and neither is a run-rate.\n- **The revenue line is milestone-shaped.** Payments from Gilead and Sanofi arrive when a partner decides they arrive; a quarter without one prints a large sequential decline that looks like deterioration.\n- **This is the second attempt at B7-H3.** Development of vobramitamab duocarmazine was discontinued in Q1 2026 after the TAMARACK programme. The target has a company-specific failure already on the record, and the wider B7-H3 ADC field includes Daiichi Sankyo/Merck's ifinatamab deruxtecan, so a competitor readout can reprice MGNX without MacroGenics reporting anything.\n- **1020P is a poster, not an oral, and the data is interim Phase 1.** A Stage 1 threshold clearance in a single-arm Simon design is permission to keep enrolling, not evidence of a registrational path. The bar the market applies on 2026-10-23 is response durability and the endometrial/melanoma/sarcoma cohorts, neither of which has been quantified publicly.\n- **Runway through 2028 removes the forced raise, and a price near a 52-week high removes the excuse not to raise.** With 63,645,711 shares outstanding, a post-data shelf takedown into strength is the standard financing pattern for a name in this position.\n- **Governance churn:** Karen Ferrante, M.D. resigned from the board effective 2026-09-01, stated as personal reasons with no disagreement over operations or policies (8-K).\n\n## Setup & Price Structure\n\nThe 2026-09-04 close was $4.40, 9.5% under the 52-week high of $4.86, with a three-month price change of +13.4% and RSI(14) at 62.1. That is a name pressed into the top of its own one-year range but not stretched on momentum — 62.1 is an advancing tape, not an exhausted one.\n\nThe structure that matters is the $4.86 ceiling: the summer news flow (07-23, 08-11, 08-17) lifted price toward it and has not carried it through. A weekly close above $4.86 would mark the pre-event markup breaking out of the range rather than stalling inside it. On the downside, roughly $3.90 approximates where the three-month advance began; a weekly close under that level returns the shares to their pre-catalyst range and says the market stopped paying for the ESMO slot in advance.\n\nOn crowding, the observables are mixed rather than hot. What is present: a 9.5% distance from the 52-week high, RSI at 62.1, a sell-side target raise to $11 on 2026-08-17 against a $4.40 close, and a dated event 48 days beyond the reference close that supplies a reason to hold. What is absent from the record reviewed: any equity issuance alongside the Q2 print — the cash came from the Bora sale and partner payments — and no insider-sale filings surfaced. Retail-sentiment clustering is not measurable from the data at hand and is not claimed here.\n\nNo theme cluster currently carries this name, so this is a single-name setup; the thesis does not lean on a group move and should not be read as one.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30 (est.)** — MGC030 Phase 1: first patient dosed, guided to \"third quarter of 2026\" in the 2026-08-13 release, after IND clearance ahead of schedule. Likely disclosed at the Q3 print rather than standalone.\n- **No confirmed company-dated event falls before 2026-10-05.** The window between the reference close and ESMO is empty of scheduled MacroGenics disclosure; the next hard dates sit outside 30 days.\n- **2026-10-23** — ESMO Congress 2026, poster 1020P, 15:15–16:00 CEST: MGC026 dose-escalation and preliminary tumour-specific cohort results.\n- **~early Nov 2026 (est.)** — Q3 2026 financial results.\n- **Late 2026 (company guidance)** — MGC028 (ADAM9 ADC) preliminary clinical results.\n\n## What Would Change Our Mind\n\nThe structural break is the loss of the range the summer news built. A weekly close below $3.90 unwinds the three-month advance and puts price back where it sat before the 2026-07-23 Stage 1 disclosure — at that point the market has repriced the ESMO slot to zero before it happens, and the setup is a different one.\n\nThree non-price conditions would do the same work. First, the 2026-10-23 poster comes and goes with SCCHN response data that does not extend beyond the Stage 1 bar, or with cohort-level activity in endometrial, melanoma and sarcoma that is not quantified — a catalyst that resolves into nothing is worse for this name than one that resolves badly, because there is no second dated event until the Q3 print. Second, an equity raise priced into strength, which would confirm that the 2028 runway guidance is being managed rather than relied on. Third, an ILD or ocular-toxicity signal appearing in the Madrid dataset that was not present in the 2026-07-08 enrolment snapshot — the clean safety profile at 74 patients is a load-bearing part of the differentiation claim.\n\nOn the other side, a weekly close above $4.86 with the poster still ahead would say participation is expanding into the event rather than fading into it.\n\n## Correlation Notes\n\nNo current theme cluster carries MGNX, so the read is idiosyncratic by construction. Practical correlations: small-cap biotech risk appetite (XBI-type beta, which dominates a $4 clinical-stage name on any day without company news); B7-H3 ADC read-through from Daiichi Sankyo/Merck's ifinatamab deruxtecan, where a competitor efficacy or safety print moves the target's perceived value independent of MGC026; and partner-payment dependence on Gilead (2022 collaboration, option exercised 2026-08-11) and Sanofi (TZIELD, $24.5M regulatory milestone), which makes reported revenue a function of two counterparties' decisions rather than of demand. ESMO week itself (2026-10-23 to 10-27) concentrates oncology single-name volatility, so the poster competes for attention with the full Madrid programme.",
  "first_seen": "2026-09-04",
  "last_analyzed": "2026-09-06T08:07:54+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}